CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 170 enrolled
Drug / intervention
LASIK correction of myopic refractive errorsdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01663363
NCT01663363Phase 3Completed

A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4IR™ Excimer Laser

Abbott Medical Optics·interventional·Posted Aug 13, 2012·Updated Feb 4, 2025

In Brief

A Phase 3 clinical trial evaluating LASIK correction of myopic refractive errors for Myopia. Completed, enrolled 170 participants.

Detailed Summary

The purpose of this clinical trial is to demonstrate that wavefront-guided LASIK is safe and effective for the correction of myopic refractive errors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 13, 2012
Enrollment StartAug 1, 2012
Primary CompletionMar 1, 2014
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.9 years ago

Interventions

LASIK correction of myopic refractive errorsdevice

Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System